Parents united to find a cure
  • Home
  • About Us
    • Mission Statement
    • Our Goal
    • Board of Directors
    • Scientific and Research Advisory Board
    • Strategic Plan
    • Financial Statement
    • What is Sanfilippo Syndrome?
    • Contact Us
  • How You Can Help
    • Donate
    • Host or Attend an Event
    • Products and New Items for sale to promote awareness and serve families!
    • Become an Affiliate
      • Spinning Wheels Productions and Team Sanfilippo Collaboration
  • Research
    • Research Projects
      • Research – Australia
      • Research – Canada
      • Research – France and Netherlands
      • Research – Italy
      • Research – Poland
      • Research – Spain
      • Research – United Kingdom
      • Research – United States
    • Request for Proposals
  • Therapies and Upcoming Treatments
  • Grants
  • News
    • Gene Therapy
    • Press Releases
    • Community News
    • Resource Links
  • Events

Research Projects – Spain

February 15, 2012 by Team Sanfilippo

Sanfilippo C: TBA
University of Barcelona. Department of Genetic
Dr. Daniel Grinberg dgrinberg@ub.edu
Dr. Lluïsa Vilageliu lvilageliu@ub.edu

Gene Therapy Type A
University of Barcelona
Dr. Fatima Bosch fatima.bosch@uab.es

This week in the meeting of The Committee for Orphan Medicinal Products (COMP), has been presented to the European Medicines Agency (EMEA) the drug “Adeno-associated virus vector serotype 9 expressing human sulfamidase for treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), D. Esteve Labs, S.A. – EMA/OD/171/10)

How You Can Help

There are many ways you can get involved in the great work of our organization:
  • Host or Attend an Event
  • Become an Affiliate
  • Make a Donation

Learn More About Team Sanfilippo

Team Sanfilippo Foundation Brochure

To view the Team Sanfilippo Foundation Brochure click here.

Join Team Sanfilippo & Follow Us

Return to top of page
Site Map
© 2022 Team Sanfillipo • Log in